Head to Head Comparison: Adamis Pharmaceuticals (ADMP) vs. Its Peers

Adamis Pharmaceuticals (NASDAQ: ADMP) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Adamis Pharmaceuticals to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings & Valuation

This table compares Adamis Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Adamis Pharmaceuticals $6.47 million -$19.43 million N/A
Adamis Pharmaceuticals Competitors $8.17 billion $1.09 billion 140.72

Adamis Pharmaceuticals’ rivals have higher revenue and earnings than Adamis Pharmaceuticals.

Institutional and Insider Ownership

16.7% of Adamis Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 12.2% of Adamis Pharmaceuticals shares are owned by insiders. Comparatively, 11.4% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Adamis Pharmaceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamis Pharmaceuticals 0 0 3 0 3.00
Adamis Pharmaceuticals Competitors 871 3795 6770 181 2.54

Adamis Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 150.00%. As a group, “Pharmaceuticals” companies have a potential upside of 25.72%. Given Adamis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Adamis Pharmaceuticals is more favorable than its rivals.

Risk and Volatility

Adamis Pharmaceuticals has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals’ rivals have a beta of 34.62, meaning that their average share price is 3,362% more volatile than the S&P 500.


This table compares Adamis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamis Pharmaceuticals -143.15% -57.74% -42.37%
Adamis Pharmaceuticals Competitors -2,401.92% -68.94% -7.32%

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply